Aprea Therapeutics shares Phase 1 data for cancer drug APR-1051

June 1, 2026 8:00 AM

Aprea Therapeutics Inc. (NASDAQ: APRE) presented updated Phase 1 data for its WEE1 inhibitor APR-1051 at the American Society of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found